U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07141563) titled 'A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC' on Aug. 19.
Brief Summary: The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)
Study Start Date: May 26
Study Type: OBSERVATIONAL
Condition:
Non-small Cell Lung Cancer (NSCLC)
Intervention:
DRUG: Nivolumab + platinum-based chemotherapy
According to the product label
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Bristol-Myers Squibb
Disclaimer: Curated by HT Syndication....